NEW YORK – Canopy Biosciences said Tuesday that it is expanding an existing partnership with OnRamp Bioinformatics to offer OnRamp Bio's Rosalind cloud-based genomic informatics platform to contract research organizations that use Canopy's gene expression services.
With Rosalind, Canopy customers will be able to visualize differential gene expression data from NanoString and RNA sequencing files, even if they lack other bioinformatics capabilities. The technology will also enable collaboration among researchers in disparate locations, according to St. Louis-based Canopy.
The company said that this work with OnRamp Bio will replace a legacy multiomics data analytics report at a time when Canopy is pushing into the clinical market in the wake of its December acquisition of biopharma services firm Core Diagnostics.
"The ability to dynamically visualize gene expression and pathway analysis while easily collaborating with your whole team is highly sought after, especially at a time when so many team members are working from home," Canopy Cofounder and COO Crystal Winkeler said in a statement. Winkeler said that Rosalind now includes COVID-19 information among the more than 50 databases it pulls information from.
A recent partnership between OnRamp Bio and NanoString Technologies will provide new informatics analysis capabilities for data generated on NanoString's nCounter system. Canopy said that it intends to make these features available to its customers through its relationship with OnRamp Bio.